Follow Merck & to never miss an important update.
Merck and its partner Daiichi Sankyo have voluntarily withdrawn their application for accelerated approval of a new lung cancer treatment. Accelerated approval is a faster path the FDA uses for drugs that treat serious conditions where there are few other options. The decision to pull the application follows discussions with the agency, though the companies did not share the specific concerns raised.
This is a setback for Merck's efforts to expand its oncology business before its top-selling drug loses patent protection in 2028. While the companies are still studying the drug in other trials, this withdrawal means it will take longer to reach the market for this specific group of lung cancer patients.
Source: Business Wire
Merck has signed a deal with SciBrunch Therapeutics for the global rights to SPR2015. This is an early-stage drug designed to block KRAS G12D, a specific genetic mutation that acts like a broken switch to keep cancer cells growing. These types of mutations are common in some of the hardest-to-treat cancers, including lung and pancreatic tumors.
While the drug is still in the preclinical phase, meaning it has not yet been tested in humans, it fits Merck's strategy of finding new ways to treat cancer beyond its flagship drug, Keytruda. Securing these rights early allows Merck to build out its pipeline of oral treatments that could eventually be used alongside its existing therapies.
Source: Business Wire
Merck announced that its drug remigromig succeeded in a large trial of adults with diabetic macular edema, a condition where fluid builds up in the retina and causes vision loss. The drug is designed to activate a specific biological pathway to repair the blood vessels in the eye, which could make it a first-of-its-kind treatment if it reaches the market.
This is an important win for Merck as it looks for new sources of growth beyond its top-selling cancer medicines. While this is the first of two required trials, the success suggests Merck could soon compete in the multi-billion dollar market for vision-loss treatments, helping to diversify its earnings before its biggest patents expire later this decade.
Source: Business Wire
Japan’s health ministry approved a new version of Keytruda that is injected under the skin. This subcutaneous version is much faster to give to patients than the traditional intravenous drip, which can take up to an hour in a hospital setting.
This is a key part of how Merck plans to protect its profits. The original Keytruda will lose its patent protection in a few years, which allows other companies to sell cheaper copies. By moving patients to this newer, more convenient version that has its own patent life, Merck can keep its lead in the cancer market and make it harder for rivals to take its customers.
Source: Business Wire
European regulators recommended approving Keytruda in combination with another drug for adults with a specific type of bladder cancer. This treatment would be used both before and after surgery to help prevent the cancer from returning. This recommendation is a key step toward final approval in the European Union.
While Keytruda is already the world's top-selling drug, Merck is working to expand its use into more types of cancer and earlier stages of treatment. These new approvals are vital for the company as it tries to maximize the drug's value before its patent protection expires in 2028.
Source: Business Wire
Management consistently sets a beatable bar, delivering seven beats in the last eight quarters. This pattern shows they have a tight grip on their costs and a reliable forecast for their drug sales.
| Expectation | |
|---|---|
| EPS | $2.20 |
| Revenue | $17.31B |